Sana Biotechnology (NASDAQ:SANA) Stock Price Up 9.1%

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report)'s stock price rose 9.1% during trading on Tuesday . The company traded as high as $8.80 and last traded at $8.63. Approximately 623,194 shares changed hands during trading, a decline of 79% from the average daily volume of 2,907,238 shares. The stock had previously closed at $7.91.

Wall Street Analysts Forecast Growth

SANA has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $12.00 price target on shares of Sana Biotechnology in a research report on Thursday, May 9th. JMP Securities upped their target price on Sana Biotechnology from $8.00 to $15.00 and gave the company a "market outperform" rating in a research report on Friday, March 1st.

Sana Biotechnology Trading Up 8.7 %

The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -5.58 and a beta of 1.62. The firm has a 50-day moving average of $9.05 and a 200-day moving average of $6.61.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.03. During the same quarter last year, the company posted ($0.40) earnings per share. On average, equities research analysts anticipate that Sana Biotechnology, Inc. will post -1.06 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Several institutional investors have recently made changes to their positions in the company. Deutsche Bank AG boosted its stake in shares of Sana Biotechnology by 1.8% during the 3rd quarter. Deutsche Bank AG now owns 478,482 shares of the company's stock worth $1,852,000 after acquiring an additional 8,408 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Sana Biotechnology in the third quarter valued at approximately $2,091,000. China Universal Asset Management Co. Ltd. increased its position in shares of Sana Biotechnology by 351.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,800 shares of the company's stock valued at $93,000 after buying an additional 17,753 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Sana Biotechnology by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,167,585 shares of the company's stock worth $35,479,000 after buying an additional 107,167 shares during the period. Finally, Citigroup Inc. lifted its position in shares of Sana Biotechnology by 10.3% during the 3rd quarter. Citigroup Inc. now owns 145,370 shares of the company's stock valued at $563,000 after buying an additional 13,616 shares in the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.